ACUVAIL® (ketorolac tromethamine ophthalmic solution) 0.45
... rabbits and rats at oral doses of 3.6 mg/kg/day and 10 mg/kg/day, respectively. These doses are approximately 600 times and 1700 times higher respectively than the typical human topical ophthalmic daily dose of 0.35 mg (4.5 mg/mL x 0.04 mL/drop, twice daily) to an affected eye on a mg/kg basis. Addi ...
... rabbits and rats at oral doses of 3.6 mg/kg/day and 10 mg/kg/day, respectively. These doses are approximately 600 times and 1700 times higher respectively than the typical human topical ophthalmic daily dose of 0.35 mg (4.5 mg/mL x 0.04 mL/drop, twice daily) to an affected eye on a mg/kg basis. Addi ...
Part IB Summary of Product Characteristics
... Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance. A risk of cross-hypersensitivity reactions with substituted benzimidazoles cannot be excluded. Patients should be cautioned that Rabeprazole sodium tablets should not be chew ...
... Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance. A risk of cross-hypersensitivity reactions with substituted benzimidazoles cannot be excluded. Patients should be cautioned that Rabeprazole sodium tablets should not be chew ...
PART Ⅳ AGENTS ACTING ON THE CENTRAL NERVOUS SYSTEM
... to inhibit development and spread of epileptiform activity in CNS. (2)use: convulsion and status epilepticus, injection/large dose. (3) common drug: ①clonazepam for chronic treatment of epilepsy; ②diazepam for terminating grand mal epileptic seizures and status epilepticus; ...
... to inhibit development and spread of epileptiform activity in CNS. (2)use: convulsion and status epilepticus, injection/large dose. (3) common drug: ①clonazepam for chronic treatment of epilepsy; ②diazepam for terminating grand mal epileptic seizures and status epilepticus; ...
Future Challenges - Thrombosis Research Institute
... • Most bleeding can be managed without specific ...
... • Most bleeding can be managed without specific ...
Prevention and monitoring of the side effects of chronic
... should be carefully considered. The determination whether the patient can receive other treatment for the given disease and if it has already been implemented, whether the dose is optimal. Therapeutic targets, assumed duration of therapy, the dose (the smallest dose for the shortest time period) and ...
... should be carefully considered. The determination whether the patient can receive other treatment for the given disease and if it has already been implemented, whether the dose is optimal. Therapeutic targets, assumed duration of therapy, the dose (the smallest dose for the shortest time period) and ...
Physician`s Labeling Rule_Content
... Adverse reactions that occurred in 1% to less than 5% of trial participants receiving Serostim® during the first 12 weeks of Clinical Trial 2 thought to be related to Serostim® included dose dependent edema, periorbital edema, carpal tunnel syndrome, hyperglycemia and hypertriglyceridemia. During th ...
... Adverse reactions that occurred in 1% to less than 5% of trial participants receiving Serostim® during the first 12 weeks of Clinical Trial 2 thought to be related to Serostim® included dose dependent edema, periorbital edema, carpal tunnel syndrome, hyperglycemia and hypertriglyceridemia. During th ...
Guidelines for Antipsychotic Medication Switches
... with conventional agents are suffering unacceptable side effects and those in relapse who have experienced unsatisfactory management or unacceptable side effects. Oral atypical antipsychotic monotherapy is recommended as first line therapy for first episode schizophrenia In individuals with treatmen ...
... with conventional agents are suffering unacceptable side effects and those in relapse who have experienced unsatisfactory management or unacceptable side effects. Oral atypical antipsychotic monotherapy is recommended as first line therapy for first episode schizophrenia In individuals with treatmen ...
ayout 1 - Betimol
... increases were observed in the incidences of benign and malignant pulmonary tumors, benign uterine polyps, as well as mammary adenocarcinomas. These changes were not seen at the daily dose level of 5 or 50 mg/kg (approximately 700 or 7,000, respectively, times the systemic exposure following the ma ...
... increases were observed in the incidences of benign and malignant pulmonary tumors, benign uterine polyps, as well as mammary adenocarcinomas. These changes were not seen at the daily dose level of 5 or 50 mg/kg (approximately 700 or 7,000, respectively, times the systemic exposure following the ma ...
Rough guide to follow up of Eye Casualty patients
... posterior uveitis, secondary glaucoma and cranial nerve palsy need to be seen in consultant clinic. Patient with anterior uveitis may be followed up in PCFU. GLAUCOMA: Acute Glaucoma: These patients need emergency management as per protocol and admission. Refer to suidelines for this. It is good pra ...
... posterior uveitis, secondary glaucoma and cranial nerve palsy need to be seen in consultant clinic. Patient with anterior uveitis may be followed up in PCFU. GLAUCOMA: Acute Glaucoma: These patients need emergency management as per protocol and admission. Refer to suidelines for this. It is good pra ...
Ditripentat-Heyl (DTPA) - Heyl Chemisch
... The acute LD50 of Ca-DTPA is 6.2 g/kg (mouse i.p.), whereas the animals died within 48 hours. In rats the LD50 is 3.5 g/kg (i.p.). b) Chronic toxicity Long-term studies with low doses of Ca-DTPA did not lead to side effects in mice. High doses resulted in nephrotic renal disorders, which are reversi ...
... The acute LD50 of Ca-DTPA is 6.2 g/kg (mouse i.p.), whereas the animals died within 48 hours. In rats the LD50 is 3.5 g/kg (i.p.). b) Chronic toxicity Long-term studies with low doses of Ca-DTPA did not lead to side effects in mice. High doses resulted in nephrotic renal disorders, which are reversi ...
The Drugs to Kill the Bugs: Part 1
... Percentage of bacteriologic (black bars) and clinical (hatched bars) cures as a function of AUC0-24:MIC in 68 patients with gram-negative infections treated with ciprofloxacin. Note that the bacteriologic and clinical outcomes are better with AUC > 125. ...
... Percentage of bacteriologic (black bars) and clinical (hatched bars) cures as a function of AUC0-24:MIC in 68 patients with gram-negative infections treated with ciprofloxacin. Note that the bacteriologic and clinical outcomes are better with AUC > 125. ...
cocaine
... degree of toxicity that develops. The biologic half-life of cocaine is 0.5–1.5 hours. A relatively minor amount is excreted unchanged in the urine. Benzoylecgonine and EME are also excreted in the urine , because of a long elimination half-life, assays typically detect benzoylecgonine for as long as ...
... degree of toxicity that develops. The biologic half-life of cocaine is 0.5–1.5 hours. A relatively minor amount is excreted unchanged in the urine. Benzoylecgonine and EME are also excreted in the urine , because of a long elimination half-life, assays typically detect benzoylecgonine for as long as ...
File
... A high incidence (up to 50%) of gastrointestinal and CNS side effects is produced Gastric irritation, nausea, anorexia, gastric bleeding and diarrhoea are produced Frontal headache, dizziness, ataxia, mental confusion, hallucination, depression and psychosis can occur Because of prominent adverse ef ...
... A high incidence (up to 50%) of gastrointestinal and CNS side effects is produced Gastric irritation, nausea, anorexia, gastric bleeding and diarrhoea are produced Frontal headache, dizziness, ataxia, mental confusion, hallucination, depression and psychosis can occur Because of prominent adverse ef ...
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE
... reduce the effectiveness of hexamine compounds, which are only effective as urinary antiseptics in acid urine. The renal excretion of lithium appears to be increased by sodium bicarbonate and this could lead to reduced plasma levels of lithium and impairment of the therapeutic response. ...
... reduce the effectiveness of hexamine compounds, which are only effective as urinary antiseptics in acid urine. The renal excretion of lithium appears to be increased by sodium bicarbonate and this could lead to reduced plasma levels of lithium and impairment of the therapeutic response. ...
Choline magnesium trisalicylate in patients Dworski
... serious problem since some patients show Intolerance to aspirin and other non-steroidal, antl-lnfiammatory drugs that are cyclooxygenase lnhlb· ltors. Sallcylates were belleved to be well tolerated, but recent reports have demonstrated that dlOunlsal and sallcylsallcyllc acid can precipitate asthma ...
... serious problem since some patients show Intolerance to aspirin and other non-steroidal, antl-lnfiammatory drugs that are cyclooxygenase lnhlb· ltors. Sallcylates were belleved to be well tolerated, but recent reports have demonstrated that dlOunlsal and sallcylsallcyllc acid can precipitate asthma ...
antidotesjbcole1
... indicated as part of the “coma cocktail,” as it has potentially serious side-effects and minimal benefit ...
... indicated as part of the “coma cocktail,” as it has potentially serious side-effects and minimal benefit ...
A Highly Efficacious Risedronate
... Olpadronate, Risedronate, Ibandronate, Zoledronate. Alendronate (ALE) and Risedronate (RIS) are available in Indonesia. The novel BISP, Risedronate (RIS) is 5-fold more potent than ALE. Most recent studies on PMO demonstrated that RIS of 35 mg, or 50 mg Once a Week (OaW) provided the same efficacy a ...
... Olpadronate, Risedronate, Ibandronate, Zoledronate. Alendronate (ALE) and Risedronate (RIS) are available in Indonesia. The novel BISP, Risedronate (RIS) is 5-fold more potent than ALE. Most recent studies on PMO demonstrated that RIS of 35 mg, or 50 mg Once a Week (OaW) provided the same efficacy a ...
Balancing the outcomes: reporting adverse events
... information about AEs for reporting, both in general1 and for particular classes of trial, such as chemotherapy19 or postoperative analgesia.13 The need for such guidelines is evident from studies of adequacy of AE reporting. In one evaluation of reporting of safety data from clinical trials of HIV ...
... information about AEs for reporting, both in general1 and for particular classes of trial, such as chemotherapy19 or postoperative analgesia.13 The need for such guidelines is evident from studies of adequacy of AE reporting. In one evaluation of reporting of safety data from clinical trials of HIV ...
Pharmacy Updates in Cardiology
... Failed to show non-inferiority in ADVANCE I For knee replacement vs. Enoxaparin 30mg twice daily ADVANCE 2 Apixaban was superior to Enoxaparin 40mg daily for knee replacement ADVANCE 3 Apixaban had lower rates of DVT/PE (n=27) vs. Enoxaparin 40mg daily (n=74) ...
... Failed to show non-inferiority in ADVANCE I For knee replacement vs. Enoxaparin 30mg twice daily ADVANCE 2 Apixaban was superior to Enoxaparin 40mg daily for knee replacement ADVANCE 3 Apixaban had lower rates of DVT/PE (n=27) vs. Enoxaparin 40mg daily (n=74) ...
Full Prescribing Information
... hours following the administration of other triptans. Considering the extent of use of triptans in patients with migraine, the incidence of these events is extremely low. AXERT® can cause coronary vasospasm; at least one of these events occurred in a patient with no cardiac history and with document ...
... hours following the administration of other triptans. Considering the extent of use of triptans in patients with migraine, the incidence of these events is extremely low. AXERT® can cause coronary vasospasm; at least one of these events occurred in a patient with no cardiac history and with document ...
Pharm
... Which of the following is true of cycloserine? a. Can be used for tuberculosis or mycobacterium avium complex as a first line agent b. Works by destabilizing the cell membrane in mycobacterium c. Is an antimicrobial that is effective against resistant organisms d. Can block D-alanine racemase and L ...
... Which of the following is true of cycloserine? a. Can be used for tuberculosis or mycobacterium avium complex as a first line agent b. Works by destabilizing the cell membrane in mycobacterium c. Is an antimicrobial that is effective against resistant organisms d. Can block D-alanine racemase and L ...
arrhythmias - ichapps.com
... antibody titer) occur in nearly all patients, and in the absence of symptoms, these are not an indication to stop drug therapy. Other adverse effects include nausea and diarrhea (in about 10% of cases), rash, fever, hepatitis (< 5%), and agranulocytosis (approximately 0.2%). Pharmacokinetics & Dosag ...
... antibody titer) occur in nearly all patients, and in the absence of symptoms, these are not an indication to stop drug therapy. Other adverse effects include nausea and diarrhea (in about 10% of cases), rash, fever, hepatitis (< 5%), and agranulocytosis (approximately 0.2%). Pharmacokinetics & Dosag ...
OAB Conversation Starters
... 6.1 Clinical Trials Experience: The safety of Toviaz was evaluated in Phase 2 and 3 controlled trials in a total of 2859 patients with overactive bladder, of which 2288 were treated with fesoterodine. Of this total, 782 received Toviaz 4 mg/day, and 785 received Toviaz 8 mg/day in Phase 2 or 3 studi ...
... 6.1 Clinical Trials Experience: The safety of Toviaz was evaluated in Phase 2 and 3 controlled trials in a total of 2859 patients with overactive bladder, of which 2288 were treated with fesoterodine. Of this total, 782 received Toviaz 4 mg/day, and 785 received Toviaz 8 mg/day in Phase 2 or 3 studi ...
Xofigo Treatment Guide PDF
... • stay well hydrated and report any signs of dehydration (such as dry mouth and increased thirst) or urinary or kidney problems (such as burning when urinating) • there are no restrictions regarding contact with other people after receiving Xofigo • follow good hygiene practices in order to minim ...
... • stay well hydrated and report any signs of dehydration (such as dry mouth and increased thirst) or urinary or kidney problems (such as burning when urinating) • there are no restrictions regarding contact with other people after receiving Xofigo • follow good hygiene practices in order to minim ...
Gentamicin Dosing And Therapeutic Drug Monitoring Guideline
... Gentamicin has a potentially toxic side effect profile (nephrotoxicity and ototoxicity. Gentamicin should be used with caution in any patients with an impaired renal function. Due to a reduced rate of drug clearance and the potential for accumulation, this group of patients is particularly susceptib ...
... Gentamicin has a potentially toxic side effect profile (nephrotoxicity and ototoxicity. Gentamicin should be used with caution in any patients with an impaired renal function. Due to a reduced rate of drug clearance and the potential for accumulation, this group of patients is particularly susceptib ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.